Aquablation治疗症状性良性前列腺增生:单中心47例经验
单中心连续47例症状性BPH患者接受第二代Aquablation水刀消融治疗,收集基线、围手术期及3个月排尿功能数据。结果显示手术时间与导尿时间短,并发症以Clavien-Dindo I-II及III级为主,IPSS、QoL、Qmax及PVR在3个月时均显著改善(P<0.01),证实了系统改进带来的流程优化与安全性、短期有效性。
要点
- 第二代Aquablation装置在47例BPH患者中保留安全性和短期有效性。
- 3个月IPSS由24.4降至5,Qmax由7.1升至16.5 mL/s,PVR由119降至43 mL。
- 8例出现并发症,其中Clavien-Dindo I/II级5例、III级5例。
核心结论
- 第二代Aquablation装置治疗BPH相关LUTS保留了安全性和短期有效性,并体现系统改进带来的流程优化。
研究设计与样本
- 单中心连续47例症状性BPH患者接受Aquablation治疗,收集基线、围手术期及3个月排尿功能数据。
- 患者平均年龄66岁(范围50-79岁),前列腺体积48 mL(范围20-118 mL)。
- 25例(53%)存在中叶,8例为导尿管依赖的尿潴留。
主要发现
- 平均总手术时间35 min(范围13-128 min),组织切除时间4 min(范围1-10 min)。
- 8例患者记录到10例次并发症:Clavien-Dindo I/II级5例次、III级5例次。
- 平均住院3.1天(范围1-8天),平均尿道导尿时间1.9天(范围1-11天)。
- IPSS由基线24.4降至3个月5,IPSS生活质量评分由4.5降至0.3分。
- Qmax由7.1升至16.5 mL/s,PVR由119降至43 mL(所有P<0.01)。
临床怎么用
- 对于症状性BPH患者,Aquablation可作为保留安全性和短期有效性的手术选择。
- 第二代装置的系统改进可能优化手术流程,缩短手术和导尿时间。
局限性
- 单中心、小样本(47例)、短期(3个月)随访,缺乏对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report procedure process improvements and confirm the preserved safety and short-term effectiveness of a second-generation Aquablation device for the treatment of lower urinary tract symptoms (LUTS) attributable to benign prostatic hyperplasia (BPH) in 47 consecutive patients at a single institution. PATIENTS AND METHODS: Aquablation was performed in 47 patients with symptomatic BPH at a single institution. Baseline, peri-operative and 3-month urinary function data were collected. RESULTS: The mean (range) patient age was 66 (50-79) years, and transrectal ultrasonography-measured prostate volume was 48 (20-118) mL. A median lobe was present in 25 patients (53%) and eight patients had catheter-dependent urinary retention. The mean (range) total procedure time was 35 (13-128) min and the tissue resection time was 4 (1-10) min. Five Clavien-Dindo grade I/II and five Clavien-Dindo grade III complications were recorded in eight patients. The mean (range) hospital stay was 3.1 (1-8) days and the mean (range) duration of urethral catheterization was 1.9 (1-11) days. The mean International Prostate Symptom Score (IPSS) decreased from 24.4 at baseline to 5 at 3 months; IPSS quality-of-life score decreased from 4.5 to 0.3 points; peak urinary flow rate increased from 7.1 to 16.5 mL/s and post-void residual urine volume decreased from 119 to 43 mL (all P < 0.01). CONCLUSIONS: This study confirmed procedure process improvements resulting from system enhancements, with preservation of safety and effectiveness during use of a second-generation device for the treatment of LUTS attibutable to BPH in the largest single-institution study conducted to date.
引用
- Desai MM, Singh A, Abhishek S, et al. Aquablation therapy for symptomatic benign prostatic hyperplasia: a single-centre experience in 47 patients. BJU Int. 2018. PMID: 29319914. doi:10.1111/bju.14126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。